Synagis Market 2026 strengthening RSV prevention

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Synagis Market In 2026 And What Value Is Projected For 2030?

The historical growth can be linked to a rise in RSV infection cases among infants, coupled with increasing recognition of preventive monoclonal antibody treatments. Further contributing factors include the expansion of neonatal intensive care units, the provision of reimbursement for RSV preventive measures, and the regulatory clearances granted for pediatric biological drugs.

The market expansion during the projected period is driven by several factors, including heightened investments in advanced RSV prevention treatments, a growing emphasis on long-acting monoclonal antibodies, an increase in biologic manufacturing capabilities, rising expenditure on pediatric healthcare, and the wider adoption of precision immunotherapy techniques.

Significant developments anticipated in the forecast period encompass the increasing use of monoclonal antibody-based RSV prophylaxis, a greater focus on preventive pediatric immunotherapies, the expansion of cold-chain dependent biologic distribution networks, an intensified commitment to protecting high-risk infants, and improved scalability in the production of biologics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Synagis Market?

The future expansion of the Synagis market is anticipated to be driven by the growing incidence of chronic respiratory conditions. These are long-term illnesses affecting the lungs and airways, resulting in persistent breathing difficulties. Several elements contribute to the widespread occurrence of chronic respiratory conditions, including an aging demographic, choices related to smoking and lifestyle, genetic and work-related factors, and environmental contaminants. Synagis (palivizumab) offers protection against severe respiratory syncytial virus (RSV) infections in vulnerable infants and children, thereby mitigating complications and flare-ups in individuals with chronic respiratory issues. For instance, in June 2025, the World Health Organization (WHO), a specialized UN agency based in Switzerland, reported that chronic respiratory diseases impact over 80 million people, with many cases remaining undiagnosed, as per a joint WHO and European Respiratory Society report. Consequently, the rising prevalence of chronic respiratory conditions is fueling the growth of the Synagis market.

What Are The Key Segments Of The Synagis Market?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

What Key Trends Are Influencing The Development Of The Synagis Market?

Companies operating in the Synagis market are primarily focused on achieving drug approvals to deliver preventive treatments for respiratory syncytial virus (RSV), thereby addressing a significant unfulfilled medical requirement. Drug approval constitutes the regulatory framework through which authorities evaluate a drug’s safety, effectiveness, and quality, based on data from clinical trials, prior to authorizing its use. For instance, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical company, obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventative therapy for RSV. This injection is supplied as palivizumab 100 mg/ml in single-dose vials of 50 mg/0.5 ml and 100 mg/ml for intramuscular administration. Palivizumab is prescribed for infants born at =35 weeks gestation, children needing treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This endorsement signifies the first preventive therapy for RSV to become available in India.

Who Are The Leading Companies Operating In The Synagis Market?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Read the full synagis market report here:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

What Are The Leading Geographic Regions In The Synagis Market?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Synagis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp

Browse Through More Reports Similar to the Global Synagis Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795